Parnell Pharmaceuticals Holdings Ltd. reported audited earnings results for the first quarter ended March 31, 2018. For the quarter, the company's total revenue was $5.2 million, a 107% increase compared to the same period in 2017. Earnings Before Interest, Tax, Depreciation, Amortization and Other Income improved by $3.9 million to a profit of $0.4 million compared to a $3.5 million loss for the same period in 2017. Net loss after tax improved by $7.1 million to $0.5 million compared to $7.6 million in 2017

For the year 2018, the company revised revenue guidance, as previously communicated in January 11, 2018 update, in the range of $25.0 to $26.0 million, being a 30% to 35% increase over 2017 and an EBITDAOI range of $5.0 to $6.0 million, compared to a close-to-break-even result in 2017.